Self-titration of inhaled corticosteroid and {beta}2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial

Conclusions
The timing of ICS dose when self-titrated to β2-agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed β2-agonist.

Source: European Respiratory Journal - October 8, 2020 Category: Respiratory Medicine Authors: Baggott, C., Hardy, J., Sparks, J., Holliday, M., Hall, D., Vohlidkova, A., Hancox, R. J., Weatherall, M., Fingleton, J., Beasley, R., on behalf of the PRACTICAL Study Team Tags: Asthma and allergy Original Articles: Asthma Source Type: research